

David S Baldwin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8781005/david-s-baldwin-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203
papers

6,472
citations

43
h-index

75
g-index

222
ext. papers

7,662
ext. citations

4.5
avg, IF

6.02
L-index

#	Paper	IF	Citations
203	What medical students think about measurement of their well-being: cross-sectional survey and qualitative interviews.. <i>BMJ Open</i> , 2022 , 12, e056749	3	
202	Relationship of behavioral inhibition to separation anxiety in a sample (N=1377) of adult individuals with mood and anxiety disorders.. <i>Comprehensive Psychiatry</i> , 2022 , 116, 152326	7.3	
201	Obsessive-compulsive symptoms and the Covid-19 pandemic: A rapid scoping review. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 ,	9	5
200	Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study. <i>CNS Spectrums</i> , 2021 , 1-7	1.8	
199	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine. <i>Frontiers in Psychiatry</i> , 2021 , 12, 784370	5	0
198	Patient experience of lasting negative effects of psychological interventions for anxiety and depression in secondary mental health care services: a national cross-sectional study. <i>BMC Psychiatry</i> , 2021 , 21, 578	4.2	1
197	Capacity for cortical excitation is reduced in psychotic disorders: An investigation of the TMS-EMG cortical silent period.. <i>Schizophrenia Research</i> , 2021 , 240, 73-77	3.6	
196	Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders: exploratory study. <i>International Clinical Psychopharmacology</i> , 2021 , 36, 126-132	2.2	2
195	The validity of the state-trait anxiety inventory and the brief scale for anxiety in an inpatient sample with alcohol use disorder. <i>Addiction</i> , 2021 , 116, 3055-3068	4.6	0
194	The effect of attachment security priming and oxytocin on physiological responses to trauma films and subsequent intrusions. <i>Behaviour Research and Therapy</i> , 2021 , 141, 103845	5.2	0
193	The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 125, 296-313	9	4
192	What is mental wellbeing?. <i>BJPsych Open</i> , 2021 , 7, S236-S236	5	1
191	Mental wellbeing in doctors: the measure matters! development of a core outcome set for measuring wellbeing in doctors. <i>BJPsych Open</i> , 2021 , 7, S235-S236	5	0
190	Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder?: A Case Series Using Phenelzine. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 461-464	1.7	1
189	Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively. <i>CNS Drugs</i> , 2021 , 35, 703-716	6.7	4
188	Hair cortisol concentration in anxiety disorders: exploration of relationships with symptom severity and inflammatory markers. <i>Acta Neuropsychiatrica</i> , 2021 , 33, 104-110	3.9	0
187	Ruminations and their correlates in depressive episodes: Between-group comparison in patients with unipolar or bipolar depression and healthy controls. <i>Journal of Affective Disorders</i> , 2021 , 280, 1-6	6.6	2

186	Quality of English inpatient mental health services for people with anxiety or depressive disorders: Findings and recommendations from the core audit of the National Clinical Audit of Anxiety and Depression. <i>Comprehensive Psychiatry</i> , 2021 , 104, 152212	7.3	
185	Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review. <i>Therapeutic Advances in Psychopharmacology</i> , 2021 , 11, 20451253211002320	4.9	2
184	A critical review of the definition of 'wellbeing' for doctors and their patients in a post Covid-19 era. <i>International Journal of Social Psychiatry</i> , 2021 , 67, 984-991	8.5	3
183	The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. <i>World Psychiatry</i> , 2021 , 20, 336-356	14.4	10
182	Diverse predictors of treatment response to active medication and placebo in gambling disorder. <i>Journal of Psychiatric Research</i> , 2021 , 144, 96-101	5.2	0
181	Feasibility and acceptability of transcranial stimulation in obsessive-compulsive symptoms (FEATSOCS): study protocol for a randomised controlled trial of transcranial direct current stimulation (tDCS) in obsessive-compulsive disorder (OCD). <i>Pilot and Feasibility Studies</i> , 2021 , 7, 213	1.9	1
180	Authors' Reply to Ulrich: Comment on 'Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively'. <i>CNS Drugs</i> , 2021 , 36, 103	6.7	
179	Covid-19: doctors must take control of their wellbeing. <i>BMJ, The</i> , 2020 , 369, m1725	5.9	16
178	Drugs to Treat Anxiety and Insomnia 2020 , 268-289		
177	Brain Functional Connectivity Correlates of Response in the 7.5% CO2 Inhalational Model of Generalized Anxiety Disorder: A Pilot Study. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 268-273	5.8	1
176	A personal account of reducing and stopping antidepressant treatment. <i>International Clinical Psychopharmacology</i> , 2020 , 35, 194-200	2.2	1
175	A neurobiological framework of separation anxiety and related phenotypes. <i>European Neuropsychopharmacology</i> , 2020 , 33, 45-57	1.2	5
174	Structured review of the use of the Arizona sexual experiences scale in clinical settings. <i>Human Psychopharmacology</i> , 2020 , 35, e2730	2.3	10
173	Course and outcome of patients with alcohol use disorders following an alcohol intervention during hospital attendance: mixed method study. <i>BJPsych Open</i> , 2020 , 7, e6	5	0
172	Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk?. <i>CNS Drugs</i> , 2020 , 34, 163-169	6.7	5
171	Why we need more research into the placebo response in psychiatry. <i>Psychological Medicine</i> , 2020 , 50, 2317-2323	6.9	4
170	Pharmacological Treatment of Generalized Anxiety Disorder (GAD) 2020 , 297-318		
169	Manifesto for an international digital mental health network 2019 , 2, 14-24		11

168	Tapering of SSRI treatment to mitigate withdrawal symptoms. <i>Lancet Psychiatry, the</i> , 2019 , 6, 560-561	23.3	2
167	Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder. <i>Brain, Behavior, and Immunity</i> , 2019 , 81, 105-110	16.6	23
166	Antidepressants, withdrawal, and addiction; where are we now?. <i>Journal of Psychopharmacology</i> , 2019 , 33, 655-659	4.6	7
165	Preferential Consolidation of Emotional Memory During Sleep: A Meta-Analysis. <i>Frontiers in Psychology</i> , 2019 , 10, 1014	3.4	27
164	Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2019 , 79, 24-38	16.6	71
163	Experimental Medicine Models in Generalized Anxiety Disorder and Social Anxiety Disorder. <i>Handbook of Behavioral Neuroscience</i> , 2019 , 29, 363-374	0.7	
162	Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential. <i>American Journal of Psychiatry</i> , 2019 , 176, 966	11.9	8
161	Yogic Breathing Instruction in Patients with Treatment-Resistant Generalized Anxiety Disorder: Pilot Study. <i>International Journal of Yoga</i> , 2019 , 12, 78-83	1.6	6
160	A personal account of depressive illness and its antidepressant treatment. <i>International Clinical Psychopharmacology</i> , 2019 , 34, 286-290	2.2	1
159	Prevalence, clinical correlates and IQ of suicidal ideation in drug naïve Chinese Han patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2019 , 248, 59-64	6.6	7
158	Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder. <i>Translational Psychiatry</i> , 2018 , 8, 75	8.6	29
157	The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. <i>World Psychiatry</i> , 2018 , 17, 3-11	14.4	65
156	Effects of repeated attachment security priming in outpatients with primary depressive disorders. <i>Journal of Affective Disorders</i> , 2018 , 234, 201-206	6.6	14
155	The Effect of Prefrontal Transcranial Direct Current Stimulation on Attention Network Function in Healthy Volunteers. <i>Neuromodulation</i> , 2018 , 21, 355-361	3.1	17
154	Efficacy of vortioxetine on the physical symptoms of major depressive disorder. <i>Journal of Psychopharmacology</i> , 2018 , 32, 1086-1097	4.6	7
153	Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2018 , 33, 334-348	2.2	13
152	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. <i>Brain, Behavior, and Immunity</i> , 2017 , 62, 212-218	16.6	86
151	Identity in recovery from problematic alcohol use: A qualitative study of online mutual aid. <i>Drug and Alcohol Dependence</i> , 2017 , 174, 17-22	4.9	10

150	British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>Journal of Psychopharmacology</i> , 2017 , 31, 519-552	4.6	102
149	Oxytocin receptor and G-protein polymorphisms in patients with depression and separation anxiety. <i>Journal of Affective Disorders</i> , 2017 , 218, 365-373	6.6	14
148	Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets. <i>CNS Drugs</i> , 2017 , 31, 307-317	6.7	17
147	Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. <i>Human Psychopharmacology</i> , 2017 , 32, e2628 ^{2,3}	3.3	15
146	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 162-214	3.8	143
145	Altered executive control network resting-state connectivity in social anxiety disorder. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 47-57	3.8	23
144	A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. <i>Journal of Affective Disorders</i> , 2016 , 206, 140-150	6.6	45
143	Altruism, personal benefit, and anxieties: a phenomenological study of healthy volunteers' experiences in a placebo-controlled trial of duloxetine. <i>Human Psychopharmacology</i> , 2016 , 31, 332-40	2.3	3
142	Attentional biases in patients with alcohol dependence: influence of coexisting psychopathology. <i>Human Psychopharmacology</i> , 2016 , 31, 395-401	2.3	5
141	Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 321-65	3.8	93
140	Cancer, Benign Gynecology, and Sexual Function--Issues and Answers. <i>Journal of Sexual Medicine</i> , 2016 , 13, 519-37	1.1	10
139	The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. <i>Journal of Psychopharmacology</i> , 2016 , 30, 242-52	4.6	81
138	Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1062-9	1.2	15
137	Safety and Tolerability of Antidepressants 2016 , 149-166		1
136	Utility of the Health of the Nation Outcome Scales (HoNOS) in Predicting Mental Health Service Costs for Patients with Common Mental Health Problems: Historical Cohort Study. <i>PLoS ONE</i> , 2016 , 11, e0167103	3.7	9
135	Pharmacology for sleep disturbance in PTSD. <i>Human Psychopharmacology</i> , 2016 , 31, 156-63	2.3	25
134	Genetic mechanisms of electroconvulsive therapy response in depression. <i>Human Psychopharmacology</i> , 2016 , 31, 247-51	2.3	8
133	Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder?. <i>International Clinical Psychopharmacology</i> , 2016 , 31, 347-52 ^{2,2}	2.2	16

132	The separation of adult separation anxiety disorder. <i>CNS Spectrums</i> , 2016 , 21, 289-94	1.8	16
131	Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. <i>Drug Safety</i> , 2016 , 39, 627-45	5.1	38
130	Systematic review of blood transcriptome profiling in neuropsychiatric disorders: guidelines for biomarker discovery. <i>Human Psychopharmacology</i> , 2016 , 31, 373-81	2.3	9
129	Authors' Reply to Alain Brillon's Comment on "Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence". <i>Drug Safety</i> , 2016 , 39, 1153-1154	5.1	4
128	Can cognitive behaviour therapy beneficially influence arousal mechanisms in psychosis?. <i>Human Psychopharmacology</i> , 2016 , 31, 64-9	2.3	1
127	Vortioxetine in the treatment of major depressive disorder. <i>Future Neurology</i> , 2015 , 10, 79-89	1.5	5
126	Transcranial direct current stimulation (tDCS) in the treatment of depression: Systematic review and meta-analysis of efficacy and tolerability. <i>Neuroscience and Biobehavioral Reviews</i> , 2015 , 57, 46-62	9	131
125	Poor monitoring of physical health in patients referred to a mood disorders service. <i>Therapeutic Advances in Psychopharmacology</i> , 2015 , 5, 22-5	4.9	8
124	Evaluating psychological interventions in a novel experimental human model of anxiety. <i>Journal of Psychiatric Research</i> , 2015 , 63, 117-22	5.2	17
123	Daytime intrusive thoughts and subjective insomnia symptoms. <i>Psychiatry Research</i> , 2015 , 229, 1038-42	9.9	17
122	Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. <i>Journal of Psychopharmacology</i> , 2015 , 29, 1047-60	4.6	35
121	Does previous experience of antidepressants form the expectations necessary for a placebo response?. <i>British Journal of Psychiatry</i> , 2015 , 207, 561	5.4	2
120	Cross-sectional associations of depressive symptom severity and functioning with health service use by older people in low-and-middle income countries. <i>International Journal of Environmental Research and Public Health</i> , 2015 , 12, 3774-92	4.6	4
119	Lithium and sexual dysfunction: an under-researched area. <i>Human Psychopharmacology</i> , 2015 , 30, 66-9	2.3	24
118	Early effects of duloxetine on emotion recognition in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2015 , 29, 634-41	4.6	10
117	A systematic review of the predictors of health service utilisation by adults with mental disorders in the UK. <i>BMJ Open</i> , 2015 , 5, e007575	3	44
116	Impact of Antidepressant Drugs on Sexual Function and Satisfaction. <i>CNS Drugs</i> , 2015 , 29, 905-13	6.7	33
115	Sense and Sensibility When Prescribing 'Off-Label' to Psychiatric Patients. <i>Current Pharmaceutical Design</i> , 2015 , 21, 3276-9	3.3	5

114	Investigation of cortisol levels in patients with anxiety disorders: a structured review. <i>Current Topics in Behavioral Neurosciences</i> , 2014 , 18, 191-216	3.4	37
113	The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. <i>Journal of Anxiety Disorders</i> , 2014 , 28, 741-6	10.9	20
112	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014 , 28, 403-39	4.6	387
111	Recurrent brief depression 2014 , 100-113		
110	Pharmacological Treatment of Anxiety Disorders 2014 , 865-882		1
109	Benzodiazepines: Risks and Benefits. A Reconsideration. <i>Focus (American Psychiatric Publishing)</i> , 2014 , 12, 229-234	1.1	1
108	Health literacy and the pharmacological treatment of anxiety disorders: a systematic review. <i>Human Psychopharmacology</i> , 2014 , 29, 211-5	2.3	12
107	Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. <i>Health Technology Assessment</i> , 2014 , 18, 1-59, v-vi	4.4	16
106	Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study. <i>International Clinical Psychopharmacology</i> , 2014 , 29, 339-43	2.2	3
105	Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review. <i>Acta Neuropsychiatrica</i> , 2014 , 26, 125-9	3.9	16
104	Benzodiazepines: risks and benefits. A reconsideration. <i>Journal of Psychopharmacology</i> , 2013 , 27, 967-714.6		130
103	Pharmacological treatment of panic disorder. <i>Modern Problems of Pharmacopsychiatry</i> , 2013 , 29, 128-43		11
102	Developing a European research network to address unmet needs in anxiety disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 2312-7	9	6
101	Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. <i>Depression Research and Treatment</i> , 2013 , 2013, 256841	3.8	19
100	A factor analysis of posttraumatic stress disorder symptoms using data pooled from two venlafaxine extended-release clinical trials. <i>Brain and Behavior</i> , 2013 , 3, 738-46	3.4	14
99	Quality of case reports of adverse drug reactions with psychotropic drugs: a 25-year review. <i>Human Psychopharmacology</i> , 2013 , 28, 413-20	2.3	3
98	Overcoming barriers in the pharmacological treatment of anxiety disorders. <i>Neuropsychiatry</i> , 2013 , 3, 33-44	1.8	2
97	Antidepressants for insomnia. <i>The Cochrane Library</i> , 2013 ,	5.2	1

96	Pregabalin for the treatment of generalized anxiety disorder: an update. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 883-92	3.1	47
95	A neuroimmunological perspective on anxiety disorders. <i>Human Psychopharmacology</i> , 2012 , 27, 6-14	2.3	68
94	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 13-22	5.1	17
93	Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?. <i>European Neuropsychopharmacology</i> , 2012 , 22, 137-42 ^{1,2}		14
92	A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). <i>European Neuropsychopharmacology</i> , 2012 , 22, 482-91	1.2	111
91	Psychiatry should not become hostage to placebo: an alternative interpretation of antidepressant-placebo differences in the treatment response in depression. <i>European Neuropsychopharmacology</i> , 2012 , 22, 782-6	1.2	3
90	Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. <i>Current Medical Research and Opinion</i> , 2012 , 28, 1717-24	2.5	49
89	Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function. <i>Psychopharmacology</i> , 2012 , 223, 67-73	4.7	34
88	Should benzodiazepines still have a role in treating patients with anxiety disorders?. <i>Human Psychopharmacology</i> , 2012 , 27, 237-8	2.3	6
87	Clinically relevant drug interactions in anxiety disorders. <i>Human Psychopharmacology</i> , 2012 , 27, 239-53	2.3	28
86	Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. <i>Journal of Psychopharmacology</i> , 2012 , 26, 778-83	4.6	36
85	An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 510-6	3.8	43
84	Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2012 , 27, 197-207	2.2	35
83	Inhalation of 7.5% carbon dioxide increases threat processing in humans. <i>Neuropsychopharmacology</i> , 2011 , 36, 1557-62	8.7	43
82	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011 , 261 Suppl 3, 207-45	5.1	29
81	Evidence-based pharmacological treatment of generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 697-710	5.8	97
80	Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. <i>BMJ, The</i> , 2011 , 342, d1199	5.9	190
79	Neurotic, stress-related and somatoform disorders 2010 , 453-491		2

78	Agomelatine in the treatment of mood and anxiety disorders. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2010 , 71, 153-6	0.8	
77	Manifesto for a European anxiety disorders research network. <i>European Neuropsychopharmacology</i> , 2010 , 20, 426-32	1.2	17
76	Pharmacological treatment of generalized anxiety disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2010 , 2, 453-67	3.4	20
75	Introduction to Neuropsychopharmacology By Leslie L. Iversen, Susan D. Iversen, Floyd E. Bloom and Robert H. Roth Oxford University Press. 2009. £30.00 (pb). 558pp. ISBN: 9780195380538. <i>British Journal of Psychiatry</i> , 2010 , 196, 499-500	5.4	
74	A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. <i>Current Psychiatry Reports</i> , 2010 , 12, 471-7	9.1	24
73	Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. <i>Human Psychopharmacology</i> , 2010 , 25, 17-29	2.3	58
72	The pharmacologic treatment of patients with generalized anxiety disorder: where are we now and where are we going?. <i>CNS Spectrums</i> , 2009 , 14, 5-12	1.8	6
71	Agomelatine improves symptoms of generalised anxiety disorder. <i>Evidence-Based Mental Health</i> , 2009 , 12, 54	11.1	1
70	How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. <i>Human Psychopharmacology</i> , 2009 , 24, 269-75	2.3	39
69	The generalized anxiety spectrum: prevalence, onset, course and outcome. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259, 37-45	5.1	66
68	Superiority of escitalopram to paroxetine in the treatment of depression. <i>European Neuropsychopharmacology</i> , 2009 , 19, 229-37	1.2	22
67	Research in anxiety disorders: from the bench to the bedside. <i>European Neuropsychopharmacology</i> , 2009 , 19, 381-90	1.2	48
66	Anxiety symptom severity and functional recovery or relapse. <i>Annals of Clinical Psychiatry</i> , 2009 , 21, 81-81.4		9
65	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. <i>World Journal of Biological Psychiatry</i> , 2008 , 9, 248-312	3.8	496
64	Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. <i>European Neuropsychopharmacology</i> , 2008 , 18, 422-30	1.2	69
63	Suicide by veterinary surgeons. <i>Veterinary Record</i> , 2008 , 162, 355-356	0.9	
62	Chapter 5.2 How effective are current drug treatments for anxiety disorders, and how could they be improved?. <i>Handbook of Behavioral Neuroscience</i> , 2008 , 395-411	0.7	2
61	Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. <i>Journal of Psychopharmacology</i> , 2008 , 22, 55-63	4.6	13

60	The overlap of obsessive-compulsive disorder and social phobia and its treatment. <i>CNS Spectrums</i> , 2008 , 13, 47-53	1.8	11
59	Room for improvement in the pharmacological treatment of anxiety disorders. <i>Current Pharmaceutical Design</i> , 2008 , 14, 3482-91	3.3	15
58	Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. <i>Human Psychopharmacology</i> , 2008 , 23, 527-32	2.3	22
57	Depression and Personality: Conceptual and Clinical Challenges. Edited by Michael Rosenbluth, Sidney H. Kennedy & R. Michael Bagby. American Psychiatric Publishing. 2005. 338 pp. US\$39.95 (pb). ISBN 1585621544. <i>British Journal of Psychiatry</i> , 2007 , 190, 541-542	5.4	
56	Pharmacological treatment of social phobia. <i>Psychiatry (Abingdon, England)</i> , 2007 , 6, 217-223		5
55	Development and evaluation of psychotropic drugs. <i>Psychiatry (Abingdon, England)</i> , 2007 , 6, 279-283		2
54	Discontinuation symptoms in depression and anxiety disorders. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 73-84	5.8	75
53	Escitalopram therapy for major depression and anxiety disorders. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 1583-92	2.9	114
52	Treatment of Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , 2007 , 12, 28-35	1.8	20
51	Role of pregabalin in the treatment of generalized anxiety disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 185-91	3.1	31
50	Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. <i>Journal of Psychopharmacology</i> , 2006 , 20, 91-6	4.6	47
49	Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. <i>Annals of Pharmacotherapy</i> , 2006 , 40, 1752-8	2.9	15
48	Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006 , 10 Suppl 2, 12-5	2.4	16
47	The importance of long-term tolerability in achieving recovery. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006 , 10 Suppl 1, 31-7	2.4	2
46	Generalised anxiety disorder. <i>Lancet, The</i> , 2006 , 368, 2156-66	4.0	181
45	Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?. <i>CNS Spectrums</i> , 2006 , 11, 34-9	1.8	12
44	Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. <i>British Journal of Psychiatry</i> , 2006 , 189, 264-72	5.4	99
43	A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2006 , 21, 159-69	2.2	68

42	Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 204-10	4.6	90
41	What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1428-34	4.6	153
40	Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1741-6	4.6	95
39	Symptoms of fatigue and sleepiness in major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2006 , 67 Suppl 6, 9-15	4.6	24
38	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2005 , 19, 567-96	4.6	449
37	Psychotropic Drug Directory 2003/04. The Professionals' Pocket Handbook & Aide Memoire. Stephen Bazire. Salisbury: Fivepin Publishing, 2003, £24.99 pb, 416 pp, ISBN: 0 95 448839 01. <i>Psychiatric Bulletin</i> , 2005 , 29, 239-239		
36	Evidence-based pharmacotherapy of Generalized Anxiety Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2005 , 8, 293-302	5.8	87
35	Escitalopram in the treatment of generalized anxiety disorder. <i>Expert Review of Neurotherapeutics</i> , 2005 , 5, 443-9	4.3	27
34	Short-term treatment with hypnotic drugs for insomnia: going beyond the evidence. <i>Journal of Psychopharmacology</i> , 2005 , 19, 134-5	4.6	1
33	Sexual dysfunction associated with antidepressant drugs. <i>Expert Opinion on Drug Safety</i> , 2004 , 3, 457-70	4.1	70
32	Clinical evaluation of psychotropic drugs. <i>Psychiatry (Abingdon, England)</i> , 2004 , 3, 14-17		
31	Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. <i>Psychopharmacology</i> , 2004 , 176, 466-70	4.7	54
30	Anxiety disorders: does one treatment fit all?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004 , 8 Suppl 1, 31-5	2.4	
29	Placebo-controlled studies in depression: necessary, ethical and feasible. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003 , 253, 22-8	5.1	48
28	The future of antidepressant pharmacotherapy. <i>World Psychiatry</i> , 2003 , 2, 3-8	14.4	6
27	Discharging psychiatric patients from hospital. <i>Psychiatric Bulletin</i> , 2002 , 26, 436-436		
26	Off-label prescribing. <i>Psychiatric Bulletin</i> , 2002 , 26, 394-394		
25	The economic consequences of social phobia. <i>Journal of Affective Disorders</i> , 2002 , 68, 221-33	6.6	103

24	Escitalopram: efficacy and tolerability in the treatment of depression. <i>British Journal of Hospital Medicine</i> , 2002 , 63, 668-71		8
23	Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder. <i>Expert Review of Neurotherapeutics</i> , 2002 , 2, 717-24	4.3	5
22	Can we distinguish anxiety from depression?. <i>Psychopharmacology Bulletin</i> , 2002 , 36 Suppl 2, 158-65	0.9	15
21	Unmet needs in the pharmacological management of depression. <i>Human Psychopharmacology</i> , 2001 , 16, S93-S99	2.3	11
20	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. <i>Journal of Psychopharmacology</i> , 2001 , 15, 161-5	4.6	11
19	SSRIs in the Treatment of Generalized Anxiety Disorder 2001 , 193-209		
18	Off-label prescribing by psychiatrists. <i>Psychiatric Bulletin</i> , 2000 , 24, 415-417		20
17	Clinical experience with paroxetine in social anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2000 , 15 Suppl 1, S19-24	2.2	10
16	Effects of age and gender on elderly suicide rates in Catholic and Orthodox countries: an inadvertent neglect?. <i>International Journal of Geriatric Psychiatry</i> , 2000 , 15, 904-10	3.9	30
15	Pharmacological provocation and prevention of suicidal behaviour. <i>International Review of Psychiatry</i> , 2000 , 12, 54-61	3.6	2
14	Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. <i>British Journal of Psychiatry</i> , 1999 , 175, 120-6	5.4	162
13	Overcoming challenges in the management of schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 1999 , 3, 11-5	2.4	2
12	The Asian Cultural Identity Schedule: an investigation of culture and deliberate self-harm. <i>International Journal of Methods in Psychiatric Research</i> , 1999 , 8, 212-218	4.3	18
11	More scrutiny required: An audit of the distribution of The Royal College of Psychiatrists' Help is at Hand leaflet on social phobia. <i>International Journal of Health Promotion and Education</i> , 1999 , 37, 19-21	0.8	
10	Antipsychotic drugs for non-psychotic patients: Results of a questionnaire survey of prescribing practices among Wessex psychiatrists. <i>Psychiatric Bulletin</i> , 1999 , 23, 416-418		1
9	Role of dopamine in schizophrenia and Parkinson's disease. <i>British Journal of Nursing</i> , 1998 , 7, 832-4, 836, 838-41	0.7	52
8	Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. <i>Journal of Psychopharmacology</i> , 1998 , 12, 323-9	4.6	21
7	Effects of antidepressant drugs on sexual function. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997 , 1, 47-58	2.4	34

6	The SSRIs: advantages, disadvantages and differences. <i>Journal of Psychopharmacology</i> , 1995 , 9, 163-78	4.6	79
5	Psychotropic Drugs and Sexual Dysfunction. <i>International Review of Psychiatry</i> , 1995 , 7, 261-273	3.6	16
4	Dysthymia. <i>CNS Drugs</i> , 1995 , 4, 422-431	6.7	7
3	CURRENT VIEWS ON THE ETIOLOGY AND TREATMENT OF HYPERTENSION. <i>Journal of the American Geriatrics Society</i> , 1964 , 12, 239-44	5.6	
2	Evidence-based pharmacotherapy of generalized anxiety disorder	110-127	1
1	Treatment of generalised anxiety and somatoform disorders	525-541	